Latest on Anabolic Agents for Osteoporosis Treatment

被引：2
|
作者：
di Filippo, Luigi [1 ,2 ]
Rosen, Clifford J. [3 ]
机构：
[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期
关键词：
Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;
D O I：
10.1016/j.ecl.2024.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.
引用
收藏
页码：513 / 523
页数：11
相关论文
共 50 条
  • [11] Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments
    Dede, Anastasia D.
    Makras, Polyzois
    Anastasilakis, Athanasios D.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1137 - 1144
  • [12] Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
    Konstantinos A. Toulis
    Athanasios D. Anastasilakis
    Stergios A. Polyzos
    Polyzois Makras
    Hormones, 2011, 10 : 174 - 195
  • [13] Anabolic agents: what is beyond osteoporosis?
    Liu, Y.
    Levack, A. E.
    Marty, E.
    Or, O.
    Samuels, B. P.
    Redko, M.
    Lane, J. M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (05) : 1009 - 1022
  • [14] Anabolic agents: what is beyond osteoporosis?
    Y. Liu
    A. E. Levack
    E. Marty
    O. Or
    B. P. Samuels
    M. Redko
    J. M. Lane
    Osteoporosis International, 2018, 29 : 1009 - 1022
  • [15] Anabolic agents for treating postmenopausal osteoporosis
    Meunier, PJ
    JOINT BONE SPINE, 2001, 68 (06) : 576 - 581
  • [16] Anabolic Agents: A New Chapter in the Management of Osteoporosis
    Khan, Abdul-Wahab
    Khan, Aliya
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2006, 28 (02) : 136 - 141
  • [17] Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
    Lou, Shenghan
    Wang, Lifan
    Wang, Yiwen
    Jiang, Yunduo
    Liu, Jingwei
    Wang, Yansong
    MEDICINE, 2017, 96 (52)
  • [18] Development of Ca2+ receptor antagonists as anabolic agents for the treatment of osteoporosis.
    Bhatnagar, PK
    Barton, L
    Bryan, WM
    Burgess, JL
    Callahan, JF
    DelMar, R
    Fox, J
    Gleason, JG
    Gowen, M
    Huffman, WF
    Lago, AM
    Nemeth, EF
    Nguyen, TT
    Smith, BR
    Stroup, GB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A108 - A108
  • [19] The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis
    Soper, DL
    Wang, YL
    De, BW
    DeLong, MA
    Dirr, MJ
    Soehner, ME
    Lundy, MW
    Mieling, GE
    Wos, JA
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY, 5, 2002, 507 : 303 - 307
  • [20] Assessment of Bone Quality in Osteoporosis Treatment with Bone Anabolic Agents: Really Something New?
    Ulivieri, Fabio M.
    Caudarella, Renata
    Camisasca, Marzia
    Cabrini, Daniela M.
    Merli, Ilaria
    Messina, Carmelo
    Piodi, Luca P.
    CURRENT RHEUMATOLOGY REVIEWS, 2018, 14 (01) : 53 - 61
12345